Indeed, the use of SGLT-2 inhibitors may be prioritized for patients with concomitant heart failure (HF), whereas the use of GLP-1 receptor agonists may be reserved as a better treatment option for those patients having a background of Atherosclerotic Cardiovascular Disease (ASCVD) [16]. The gene discussed is SLC5A2; the disease is atherosclerosis.